Transition Therapeutics (Toronto, ON)
CMDF Investment: $2,049,000 
Public (TSX : TTH)
Focus:Cardiovascular Diseases & Blood Products  Central Nervous System Disorders  Diabetes  
Company Website

Transition is a product-focused biopharmaceutical company; developing novel therapeutics for disease indications with large markets. The company’s lead products include regenerative therapies E1-I.N.T.™ and GLP1-I.N.T.™ for the treatment of diabetes; MS-I.E.T. for the treatment of multiple sclerosis and HCV-I.E.T. for the treatment of hepatitis C. Transition has commenced a Phase II clinical trial for MS-I.E.T. in patients with multiple sclerosis and has received clearance to initiate an exploratory Phase IIa clinical trial to evaluate efficacy; safety; and tolerability of E1-I.N.T.™ in both type I and type II diabetes patients. In addition; a phase I/II clinical trial of its product; HCV-I.E.T. in hepatitis C patients is planned for the first quarter of calendar 2005.